Episurf Medical AB

EPIS B

SE0003491562

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 08:08:39 2024-04-25 am EDT			5-day change	1st Jan Change
0.365 ^SEK	-8.41%		-48.52%	-63.13%

Apr. 24	Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 22	Episurf Medical Plans SEK120 Million Rights Issue	MT

Episurf Medical - Q1’22 Review

May 02, 2022 at 04:01 am EDT

Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes several crucial activities carried out that should ignite a more significant sales growth beyond 2022.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Episurf Medical AB

Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Episurf Medical Plans SEK120 Million Rights Issue	Apr. 22	MT
Episurf Medical AB Elects Jess Lonner as New Member of the Board of Directors	Apr. 09	CI
Episurf Medical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Sweden's Episurf Medical Secures New Patents in Asia, South Africa	Nov. 28	MT
Episurf Medical AB Receives Four Additional Patent Approval Notification	Nov. 28	CI
Episurf Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27	CI
Episurf Medical Announces 510(k) Submission for Big Toe Implant	23-10-20	CI
Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024	23-10-17	CI
Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress	23-09-28	CI
Episurf Medical Announces Prospective Episealer Talus Clinical Study	23-09-13	CI
Episurf Medical's New Knee Joint Implant System Scheduled For Surgery Use in US	23-08-23	MT
Episurf Medical AB Announces First Commercial Case in the US Has Been Scheduled for Surgery	23-08-23	CI
Episurf Announces Results from the Use of Episealer Accepted for Publication in Scientific Journal	23-07-31	CI
Episurf Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
Episurf Medical Wins Hospital Value Analysis Committee's Approval for Implant System	23-07-07	MT
Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Episurf Medical Builds US Distributor Network for Episealer Patellofemoral System	23-04-11	MT
Episurf Medical Receives Another Granted Patent in India	23-03-02	CI
Episurf Medical Receives Another Notice of Allowance from the United States Patent and Trademark Office	23-03-01	CI
Episurf Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-17	CI
Episurf Medical AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-17	CI
Episurf Medical AB Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors	23-02-13	CI
Episurf Medical AB Receives Notice of Allowance from the United States Patent and Trademark Office	23-02-02	CI
Episurf Medical Wins US FDA Approval for Patellofemoral Implant System	22-12-27	MT

Episurf Medical AB is a Sweden-based medical technology company. It is engaged in the development, manufacture and marketing of implants and surgical drilling templates used in the treatment of local cartilage damage in knee joints. The Companyâs product portfolio includes the Episealer, and individually customized implant used as a cartilage replacement for early-stage patients; and Epiguide, a drill guide designed to attach to the kneeâs surface, as well as related surgical tools. The personalization of implants and instruments is based on magnetic resonance imaging (MRI) and enables less invasive treatment. The process of ordering and creation of patient-specific implants and surgical instruments is covered by software suite, microiFidelity, comprising microiClinic, microiDesign and microiManufacture. The main shareholder of the Company is Serendipity Ixora Fund AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-22 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Episurf Medical AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
EPISURF MEDICAL AB	-63.13%	9.79M
STRYKER CORPORATION	+12.49%	128B
SMITH & NEPHEW PLC	-8.90%	10.66B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-2.20%	8.55B
INSPIRE MEDICAL SYSTEMS, INC.	+15.12%	7.1B
GLAUKOS CORPORATION	+26.97%	5.06B
AXONICS, INC.	+7.09%	3.4B
ENOVIS CORPORATION	+0.27%	3.08B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-10.28%	2.11B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-8.61%	2.03B

Medical Devices & Implants

Episurf Medical AB

Equities

EPIS B

SE0003491562

Medical Equipment, Supplies & Distribution

Episurf Medical - Q1’22 Review

Latest news about Episurf Medical AB

Chart Episurf Medical AB

Company Profile

Income Statement Evolution

Ratings for Episurf Medical AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Medical Devices & Implants